Watch for Andexxa, a New Anticoagulant Reversal Agent

Andexxa (an-DEK-sah, inactivated recombinant factor Xa) will be a new, IV direct oral anticoagulant (DOAC) reversal agent.

Until now, the only reversal agent for the DOACs was Praxbind (idarucizumab). But it only reverses Pradaxa (dabigatran)...a direct thrombin inhibitor.

Andexxa will be bigger's an antidote for two factor Xa inhibitors, Eliquis (apixaban) or Xarelto (rivaroxaban).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote